{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:06:06Z","timestamp":1793279166359,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["113202001"],"award-info":[{"award-number":["113202001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","award":["WI213008"],"award-info":[{"award-number":["WI213008"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cgh.2026.06.029","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:21:40Z","timestamp":1783178500000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomized Trial Comparing 5-Year Follow-Up of First-Line Infliximab to Conventional Therapy in Pediatric Crohn\u2019s Disease"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2710-7241","authenticated-orcid":false,"given":"Stephanie A.","family":"Vuijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.E.","family":"Jongsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martinus A.","family":"Cozijnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel","family":"van Pieterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim G.J.","family":"de Meij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Groeneweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victorien M.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"van Wering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Hojsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaija-Leena","family":"Kolho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thalia","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Stapelbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathelijne","family":"van der Feen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"van Rheenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel P.","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Teklenburg-Roord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Pruijsen-Nienhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Rizopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna C.","family":"Escher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke N.","family":"Samsom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.06.029_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2026.06.029_bib2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ibd.21152","article-title":"Natural history of Crohn's disease: Comparison between childhood- and adult-onset disease","volume":"16","author":"Pigneur","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.029_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gut.2009.187120","article-title":"Early Crohn disease: a proposed definition for use in disease-modification trials","volume":"59","author":"Peyrin-Biroulet","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.06.029_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn'S disease (profile): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.029_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.06.029_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2016-000123","article-title":"Top-down infliximab study in kids with Crohn's disease (tiskids): an international multicentre randomised controlled trial","volume":"3","author":"Cozijnsen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.029_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.06.029_bib8","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.029_bib9","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/ibd\/izad307","article-title":"Infliximab monotherapy vs combination therapy for pediatric Crohn's disease exhibit similar pharmacokinetics","volume":"30","author":"Colman","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.029_bib10","first-page":"557","article-title":"The impact questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease","volume":"35","author":"Otley","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2026.06.029_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/MPG.0b013e3182165d10","article-title":"Validation of an instrument to measure quality of life in British children with inflammatory bowel disease","volume":"53","author":"Ogden","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2026.06.029_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"Euroqol-a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.cgh.2026.06.029_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.06.029_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ibd.21649","article-title":"Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions","volume":"18","author":"Turner","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.029_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"Acg clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.06.029_bib16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/ecco-jcc\/jjad049","article-title":"Serum immune profiling in paediatric Crohn's disease demonstrates stronger immune modulation with first-line infliximab than conventional therapy and pre-treatment profiles predict clinical response to both treatments","volume":"17","author":"Jongsma","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.029_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1203\/00006450-200003000-00006","article-title":"Continuing positive secular growth change in the Netherlands 1955-1997","volume":"47","author":"Fredriks","year":"2000","journal-title":"Pediatr Res"},{"key":"10.1016\/j.cgh.2026.06.029_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/adc.82.2.107","article-title":"Body index measurements in 1996-7 compared with 1980","volume":"82","author":"Fredriks","year":"2000","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cgh.2026.06.029_bib19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2471\/BLT.07.043497","article-title":"Development of a who growth reference for school-aged children and adolescents","volume":"85","author":"de Onis","year":"2007","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.cgh.2026.06.029_bib21","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/apt.18000","article-title":"Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease","volume":"59","author":"Vuijk","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.06.029_bib22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ecco-jcc\/jjad197","article-title":"Improved clinical outcomes with early anti-tumour necrosis factor alpha therapy in children with newly diagnosed Crohn's disease: Real-world data from the international prospective PIBD-setquality inception cohort study","volume":"18","author":"Klomberg","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.029_bib23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease","volume":"119","author":"Markowitz","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.06.029_bib24","article-title":"The medical management of paediatric Crohn's disease: an ecco-espghan guideline update","volume":"15","author":"van Rheenen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.029_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.06.029_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with anti-tumor necrosis factor-\u03b1 vs an immunomodulator in children with Crohn's disease","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.06.029_bib27","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (calm): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.06.029_bib28","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/apt.15094","article-title":"Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood","volume":"49","author":"Ashton","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.06.029_bib29","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.cgh.2025.05.015","article-title":"Perianal disease in pediatric-onset Crohn's disease: incidence, disease course, and long-term outcomes","volume":"24","author":"Str\u00f6m","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.029_bib30","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.cgh.2022.01.051","article-title":"New therapeutic strategies have changed the natural history of pediatric Crohn's disease: a two-decade population-based study","volume":"20","author":"Ley","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.029_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00384-024-04634-7","article-title":"The need for surgery in pediatric patients with inflammatory bowel disease treated with biologicals","volume":"39","author":"Kolho","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.cgh.2026.06.029_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf231.005","article-title":"Op05 profile 4-year follow-up shows that early effective \u201ctop-down\u201d therapy is associated with reduced long-term Crohn\u2019s disease complications","volume":"20","author":"Noor","year":"2026","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.06.029_bib33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/apt.15482","article-title":"Letter: anti-TNF therapy and intestinal resections in Crohn's disease-are we just delaying the inevitable?","volume":"50","author":"Ashton","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.06.029_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.06.029_bib35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","article-title":"Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations","volume":"70","author":"Winter","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2026.06.029_bib36","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.06.029_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.dld.2023.04.017","article-title":"Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: a population-based study","volume":"56","author":"Fumery","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2026.06.029_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/apt.14865","article-title":"Systematic review with meta-analysis: anxiety and depression in children and adolescents with inflammatory bowel disease","volume":"48","author":"Stapersma","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.06.029_bib39","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-Part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2026.06.029_bib40","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"Stride-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652600488X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652600488X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:16:18Z","timestamp":1786533378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652600488X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S154235652600488X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.06.029","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Trial Comparing 5-Year Follow-Up of First-Line Infliximab to Conventional Therapy in Pediatric Crohn\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}